Skip to main content
Premium Trial:

Request an Annual Quote

Flemish Government Provides $2.5M to Biocartis to Develop Cancer Tests

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis today announced a €1.9 million ($2.5 million) subsidy from the Flemish government for the development of diagnostic cancer tests.

The funding is for a two-year period, during which Biocartis will develop tests to run on its fully automated system. The tests will be directed at the detection of known, validated oncogenes "and allow for more targeted treatment of certain cancers," Biocartis said.

The company plans to focus on skin, colon, and lung cancer. It will also seek to develop tests to simultaneously detect "dozens of parameters" for use on its Dynamic Multi-Analyte Technology, or DMAT, platform, a multiplex detection platform for the research market.

The system was launched in December. At the time the company announced the completion of a $45 million Series D financing round.

"Oncology is our company’s primary focus for the development of diagnostic tests," Erwin Sablon, head of Applied Assay Development for Biocartis, said in a statement. "This grant will speed up the development of a broad range of clinically relevant tests that will help make cancer treatment more efficient and personalized as well as improve survival rates for patients."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.